Remodelin, an inhibitor of NAT10, significantly suppressed the growth of HNSCC in a PDX model, indicating that Remodelin may be a new candidate drug for HNSCC treatment. The gene discussed is NAT10; the disease is head and neck squamous cell carcinoma.